Phase 3Completed
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk (AMG145)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia
- Sponsor
- Amgen (Industry)
- Enrollment
- 409 enrolled
- Conditions
- Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
- Interventions
- Atorvastatin; Evolocumab; Placebo to Evolocumab
- Ages
- adults, older adults
- Registry
- NCT01953328
Full record on ClinicalTrials.gov
From the registry
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in combination with statin therapy in adults with high cardiovascular risk and with hyperlipidemia or mixed dyslipidemia.
Primary outcomes
- Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12
- Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
History
Results first posted
Last registry update
Primary completion
Started
Registered